Profile
| Metric | Value |
|---|---|
| Full Name | uniQure N.V. |
| Ticker | NASDAQ: QURE |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Netherlands |
| IPO | |
| Indexes | Not included |
| Website | uniqure.com |
| Employees | 209 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $23.08 | |
| Price, 1D Change | +3.45% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.03 | |
| Revenue | $27M | |
| Revenue, 1Y Change | +71.17% | |
| EPS | -$4.92 | |
| EPS, 1Y Change | +23.90% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$4.92 | |
| EPS Estimate | -$3.35 | |
| EPS Est. Change | +31.96% | |
| Revenue | $27.12M | |
| Revenue Estimate | $13.96M | |
| Revenue Est. Change | -48.52% | |
| Current Price | $23.08 | |
| Price Target | - | $54.62 |
| Price Tgt. Change | - | +136.64% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$6.31 | -$6.47 | -2.55% | |
| -$3.73 | -$4.92 | -32.15% | |
| -$3.35 | N/A | +31.96% | |
| -$2.66 | N/A | +46.00% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $20.85M | $15.84M | -24.01% | |
| $37.66M | $27.12M | -28.00% | |
| $13.96M | N/A | -48.52% | |
| $47.21M | N/A | +74.07% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +30.84% | |
| Price, 3Y | +0.48% | |
| Market Cap, 1Y | +66.24% | |
| Market Cap, 3Y | +33.26% | |
| Revenue, 1Y | +71.17% | |
| Revenue, 3Y | -94.82% | |
| EPS, 1Y | +23.90% | |
| EPS, 3Y | -169.98% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $23.08 | |
| SMA 200 | $23.18 | |
| SMA 200 vs Price | +0.43% | |
| SMA 50 | $29.83 | |
| SMA 50 vs Price | +29.25% | |
| Beta | 1.03 | |
| ATR | $1.82 | |
| 14-Day RSI | 41.37 | |
| 10-Day Volatility | 42.78% | |
| 1-Year Volatility | 270.20% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $27.12M | |
| EPS | -$4.92 | |
| Gross Profit | -$3.85M | |
| Gross Margin | -14.19% | |
| Operating Profit | -$184.27M | |
| Operating Margin | -679.50% | |
| Net Income | -$239.56M | |
| Net Margin | -883.35% | |
| EBITDA | -$171.63M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | -74.20 | |
| Current Ratio | 9.74 | |
| Quick Ratio | 9.74 | |
| - | ||
| F-Score | 3 | |
| Altman Z-Score | -1.60 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 91.28 | |
| PB Ratio | 6.29 | |
| EV/EBITDA | -7.21 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | -$6.75M | |
| Cash & Equivalents | $158.93M | |
| Total Assets | $556.54M | |
| Current Assets | $390.29M | |
| Total Liabilities | $563.29M | |
| Current Liabilities | $40.05M | |
| Total Debt | $500.99M | |
| Short Term Debt | $3.60M | |
| Accounts Payable | $7.23M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $266.68M | |
| Operating Expenses | $180.43M | |
| Cost Of Goods Sold | $30.97M | |
| SG&A | $0.00 | |
| D&A | $12.64M | |
| Interest Expense | $0.00 | |
| Income Tax | $2.43M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$182.73M | |
| CFI | $162.97M | |
| CFF | -$59.49M | |
| Capex | $11.69M | |
| Free Cash Flow | -$194.42M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Stifel | → | |
| Mizuho | → | |
| Chardan Capital | → | |
| Wells Fargo | → | |
| Chardan Capital | → | |
| Leerink Partners | → | |
| William Blair | → | |
| RBC Capital | → | |
| HC Wainwright & Co. | → | |
| Goldman Sachs | → |
Analyst sentiment
Institutional ownership
Screeners with QURE
Data Sources & References
- QURE Official Website www.uniqure.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1590560/000110465925108813/0001104659-25-108813-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1590560/000155837025001699/0001558370-25-001699-index.htm
- QURE Profile on Yahoo Finance finance.yahoo.com/quote/QURE
- QURE Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/qure
FAQ
What is the ticker symbol for uniQure N.V.?
The ticker symbol for uniQure N.V. is NASDAQ:QURE
Does uniQure N.V. pay dividends?
No, uniQure N.V. does not pay dividends
What sector is uniQure N.V. in?
uniQure N.V. is in the Healthcare sector
What industry is uniQure N.V. in?
uniQure N.V. is in the Biotechnology industry
What country is uniQure N.V. based in?
uniQure N.V. is headquartered in Netherlands
When did uniQure N.V. go public?
uniQure N.V. initial public offering (IPO) was on February 5, 2014
Is uniQure N.V. in the S&P 500?
No, uniQure N.V. is not included in the S&P 500 index
Is uniQure N.V. in the NASDAQ 100?
No, uniQure N.V. is not included in the NASDAQ 100 index
Is uniQure N.V. in the Dow Jones?
No, uniQure N.V. is not included in the Dow Jones index
When was uniQure N.V. last earnings report?
uniQure N.V.'s most recent earnings report was on November 10, 2025
When does uniQure N.V. report earnings?
The next expected earnings date for uniQure N.V. is February 26, 2026